Anilocus provides comprehensive mutagenicity testing services including bacterial mutation assays, mammalian cell gene mutation studies, and in vivo mutagenicity testing to assess genetic mutation potential and support regulatory submissions for drug development programs.
Anilocus provides comprehensive genotoxicity testing services including Ames test, micronucleus assay, chromosomal aberration studies, and comet assay to assess DNA damage potential and mutagenic risk for regulatory compliance and drug safety evaluation.
Anilocus provides comprehensive general toxicology studies including acute, subacute, and chronic toxicity testing with MTD determination, NOAEL estimation, and dose-range finding to evaluate drug safety and establish appropriate dosing parameters for regulatory submissions.
Anilocus provides comprehensive preclinical toxicology testing services including general toxicity, clinical pathology, genotoxicity, reproductive toxicology, and safety pharmacology studies to support drug development programs from early discovery through regulatory submission with expert scientific guidance.
Bold ideas and breakthrough research. Expert analysis on the innovations and drug development for the most important people in the world: patients.
Use this form to send your questions to our research team about our preclinical contract research services.
We are here to help!
